Jefferies Global Healthcare Conference
Logotype for GSK plc

GSK (GSK) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for GSK plc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

ViiV and long-acting HIV medicines

  • Broad phase III testing of dolutegravir across suppressed, treatment-naive and high-viral-load populations supported a broad label; the medicine became a standard-of-care oral integrase inhibitor.

  • Long-acting R&D focused on patients facing stigma, anxiety or difficulty accessing care; Cabenuva, the first long-acting HIV treatment, is given every two months and is performing well.

  • CUATRO, a pivotal study of reformulated cabotegravir and rilpivirine for four-month dosing, is fully recruited; data are expected in H2 next year, with potential launch in 2028.

  • Next-generation integrase inhibitor 184 and a capsid inhibitor are in phase II; pivotal studies could start around mid-2028, with potential market entry in the early 2030s and at least half of treatment patients potentially switching to six-month dosing.

  • Four-month Apretude PrEP data are in-house and under regulatory discussion; confidence was expressed in the formulation, which is the same as the four-month cabotegravir treatment formulation.

Business development and portfolio

  • BD has been active since the consumer business demerger; Nuvalent added precision oncology assets targeting ALK and ROS1, with ROS1 approved and ALK approval expected imminently.

  • RAPT Therapeutics brought a food-allergy antibody with every-12-week dosing and potential use in patients whose BMI or weight limits Xolair dosing; food allergy affects 18 million people in the U.S.

  • Oncology BD is expected to continue; the portfolio includes Hansoh B7-H3 and B7-H4 ADCs, with a small-cell lung cancer filing possible as early as next year and five pivotal B7-H4 studies in ovarian and endometrial cancer.

  • Chinese phase I licensing is a preferred area: human data can de-risk assets while pivotal studies and supply chains are developed for target markets; Hansoh studies run about 18 months ahead, and Western phase II results have closely replicated them.

  • Deal capacity is replenishing, with operating cash flow expected above £10bn this year and leverage at 1.8x; A2 credit rating is a constraint, and typical deals of $2bn-$3bn are preferred over another $10bn transaction.

Growth outlook and execution

  • More than 20 phase III programs started this year; readouts in the next few years are described as the growth backbone. Current-year outlook was upgraded to the top end of 3%-5% sales growth and 7%-9% operating profit growth.

  • Strong growth is expected next year, without operating-margin decline; U.S. Tivicay and Triumeq exclusivity ends in April 2028, Dovato follows at the end of 2029, and HIV declines are expected mainly in 2029-2030.

  • Long-acting HIV growth will offset some oral-product decline; sales are expected to exceed £40bn in 2031 versus ~£35bn this year, driven by specialty medicines, oncology, respiratory and vaccines.

  • After dolutegravir exclusivity ends in the early 2030s, pipeline contributions across ADCs, liver disease, respiratory biologics, HIV, vaccines and oncology could accelerate growth to top-quartile industry levels.

  • A £1.9bn cost program is planned by 2029, with most savings reinvested in R&D; BD will continue alongside execution of the pipeline and restructuring.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from GSK